Study of HPN424 in Patients With Advanced Prostate Cancer

NCT03577028 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

104

Enrollment

INDUSTRY

Sponsor class

Stopped Decision not to continue to the expansion portion of the study

Conditions

Advanced Prostate Cancer

Interventions

BIOLOGICAL: HPN424 Fixed IV 1.3 to 150 ng/kg
BIOLOGICAL: HPN424 Prime Step IV 36 ng/kg Target
BIOLOGICAL: HPN424 1 Prime Step IV 225-300 ng/kg Target
BIOLOGICAL: HPN424 2 Prime Step IV 300 ng/kg Target
BIOLOGICAL: HPN424 2 Prime Step IV 450 ng/kg Target
BIOLOGICAL: HPN424 Fixed SC

Sponsor

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)